We build cross-functional teams made up of research scientists, hardware and software engineers, physicians and commercial experts. Our multidisciplinary teams have access to advanced research tools, large scale computing power and unique technical expertise.
Andy Conrad, Ph.D.Chief Executive Officer
Formerly the chief scientific officer of LabCorp, Andy is a cell biologist with a doctorate from UCLA. He has always been passionate about early detection and prevention of disease. Andy co-founded the National Genetics Institute, which developed the first cost-effective test to screen for HIV in the blood supply.
Jessica Mega, M.D., M.P.H.Chief Medical Officer
Jessica leads Verily’s healthcare team, which informs and studies Verily’s products, creates health platforms, and translates them into systems that improve outcomes. She is a cardiologist who trained and practiced at Massachusetts General Hospital and Brigham and Women’s Hospital. As a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group, Jessica directed large, international clinical trials. She received her A.B. from Stanford University, M.D. from Yale University School of Medicine and M.P.H. from the Harvard School of Public Health.
Brian Otis, Ph.D.Chief Technical Officer
Brian’s team focuses on end-to-end innovation ranging from integrated circuits to biocompatible materials to sensors. He joined Verily from the University of Washington Department of Engineering as founder of the smart contact lens project. He leads the company’s efforts across all hardware and device projects, including wearables, implanted devices and technology including Liftware. Previously, Brian held positions at the University of Washington Kelly Tremblay Brain and Behavior Laboratory, the UC-Berkeley Ralph Freeman Neuroscience Lab, Intel Corporation and Agilent Laboratories. He received his M.S. and Ph.D. in Electrical engineering, in the field of low power integrated circuits for wireless sensors, from the University of California, Berkeley.
Tom StanisHead of Software
Tom leads all of Verily's software projects, including the development of machine learning algorithms for applications ranging from robotic-assisted surgery to diabetes management. Prior to joining Verily, he spent nine years working on core Google products and five years at Electronic Arts. Throughout his career, Tom's focus has been on improving the user experience, performance and scalability of systems through cross-functional collaboration. He received his B.S. from UW Madison.
Linus UpsonHead of Engineering
Linus Upson joined Google in 2005 and is a vice president at Verily. He leads Verily’s Debug Project and oversees engineering and user experience. Earlier he was responsible for overseeing Google’s browser products including Chrome and Chrome OS. Prior to Google, Linus was an engineer NeXT and Netscape and co-founded two companies, AvantGo and Qurb. Linus is on an extended leave from his undergraduate studies in mathematics at Princeton University.
Denny AusielloView Bio
Denny Ausiello, M.D., is the Jackson Distinguished Professor of Clinical Medicine, director, emeritus of the M.D./Ph.D. Program at Harvard Medical School, and director, Center for Assessment Technology and Continuous Health at Massachusetts General Hospital. He has made substantial contributions to the knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. Denny has been advising Verily on its diabetes initiatives, clinical study designs and device development since 2015. Denny received his M.D. from the University of Pennsylvania.
Dimitri AzarView Bio
Dimitri Azar, M.D., M.B.A., is the dean of the University of Illinois College of Medicine. Dimitri is an ophthalmic surgeon who has made significant contributions to the treatment of corneal diseases and to advances in refractive surgery. He has served as a key adviser on the Alcon and Verily ophthalmic lens projects since 2014. Dimitri completed his residency and fellowship at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. He was professor of ophthalmology at Harvard Medical School before joining the University of Illinois as head of the Ophthalmology Department. Dimitri received his M.D. from American University of Beirut and his M.B.A. from University of Chicago, Booth School of Business.
Vikram (Vik) BajajView Bio
Vikram (Vik) Bajaj
Vik Bajaj, Ph.D., is a co-founder of Verily and currently serves as the chair of the Science Board. He is head of precision medicine and translational science at Grail Bio, an associate professor of radiology (consulting) at Stanford University, and an affiliate scientist of the University of California, Berkeley and the Lawrence Berkeley National Laboratory. Vik’s research interests in industry and as a former academic principal investigator include structural and systems biology, molecular imaging, nanoscience and bioinformatics. Vik received his Ph.D. in physical chemistry from MIT.
David BrailerView Bio
David Brailer, M.D., Ph.D., is a health care technology investor and entrepreneur and an advisor to Verily. He was previously the nation’s first National Coordinator for Health Information Technology from 2004 through 2006, serving under President George W. Bush. He joined the Verily Scientific Board in 2016. David received his Ph.D. in managerial economics from The Wharton School and his M.D. from West Virginia University.
Karl DeisserothView Bio
Karl Deisseroth, Ph.D., is the D.H. Chen Professor of Bioengineering and professor of psychiatry and behavioral sciences at Stanford University. His research focuses on developing molecular and cellular tools to observe, perturb and re-engineer brain circuits. Additionally, he works as a clinician in the psychiatry department at Stanford. Karl joined the Verily board in 2016. He received his M.D. and Ph.D. from Stanford University.
Frank FischerView Bio
Frank Fischer is president and CEO of NeuroPace, a medical device company focused on the treatment of neurologic disorders with epilepsy as its first therapeutic indication. Frank has over 35 years in the medical device industry with the majority of his career dedicated to the development, clinical evaluation, regulatory approval and commercialization of products to treat cardiac and neurologic disorders. He joined the Verily Scientific Board in 2016. Frank received his M.S. in management from Rensselaer Polytechnic Institute.
Michael FrumkinView Bio
Michael Frumkin has been an engineering director at Google since 2002 where he oversee large engineering teams as well as critical internal software infrastructure projects. In 2014, Michael was also an advisor to Khosla Ventures. Currently he is leading a Google Research team that he founded, the aim of which is to bring Google’s expertise in machine intelligence and perception to bear on fundamental scientific research. Michael has been advising on Verily projects since 2014. Michael graduated with a Master of Science in computer science and engineering from MIT.
Sanjiv Sam GambhirView Bio
Sanjiv Sam Gambhir
Sam Gambhir, M.D., Ph.D., is the Virginia and D.K. Ludwig Professor in Cancer Research and chairman of the Department of Radiology at Stanford University School of Medicine. His research focuses on the molecular imaging of living subjects with a particular emphasis on early cancer detection. He is a principal investigator on the Baseline Study and has been an advisor to Verily since its inception. Sam received his M.D. and Ph.D. from the University of California, Los Angeles.
George LoewensteinView Bio
George Loewenstein, Ph.D., is the Herbert A. Simon University Professor of Economics and Psychology, co-director of the BEDR Policy Lab at Decision Research at Carnegie Mellon University, and the director of behavioral economics at the Center for Health Incentives and Behavioral Economics at the University of Pennsylvania. George is a founder of the field of behavioral economics and neuroeconomics. His current research focuses on various aspects of information and beliefs. George joined the Verily Scientific Board in 2016. He received his Ph.D. from Yale University.
Nicholas (Nik) SchorkView Bio
Nicholas (Nik) Schork
Nicholas (Nik) Schork is director of human biology at the J. Craig Venter Institute, Distinguished Professor at the Translational Genomics Research Institute, and adjunct professor at the University of California, San Diego. His interests and expertise are in quantitative human genetics and integrated approaches to complex biological and medical problems. Nik has been advising Verily on bioinformatics and genomic research since 2015. He received his Ph.D. in epidemiology from the University of Michigan in Ann Arbor.
Daniel Von HoffView Bio
Daniel Von Hoff
Daniel Von Hoff, M.D., F.A.C.P., is physician in chief and director of translational research at TGen (Translational Genomics Research Institute. He is also chief scientific officer for US Oncology Research and for HonorHealth’s Clinical Research Institute. The focus of his career has been on developing new anti-cancer agents, and more recently, on the development of molecularly targeted therapies for individuals with pancreatic cancer. Dan joined the Verily Scientific Board in 2016. He received his M.D. from Columbia University College of Physicians and Surgeons.
David WemmerView Bio
David Wemmer, Ph.D., is the Joel Hildebrand Distinguished Professor and chair of the Department of Chemistry at the University of California, Berkeley. David’s research focuses on biophysical chemistry with the goal of understanding the interactions that govern the function of biopolymers including proteins, DNA and RNA. David has been a scientific advisor for Verily since 2015. He received his Ph.D. in physical chemistry from the University of California, Berkeley.